Coherus BioSciences

At Coherus BioSciences, Inc., we are at the forefront of biopharmaceutical innovation, dedicated to revolutionizing cancer treatment through the research, development, and commercialization of novel immunotherapies. Our core mission is to deliver groundbreaking medicines that significantly improve outcomes and extend survival for patients battling hard-to-treat tumors. Through pioneering science and a commitment to excellence, we are building a leading oncology company, leveraging our in-house expertise and an established infrastructure derived from our diversified portfolio of FDA-approved therapeutics. Our innovative immuno-oncology pipeline features multiple antibody immunotherapy candidates meticulously designed to enhance both innate and adaptive immune responses. This strategic focus aims to cultivate a robust antitumor immunologic reaction, ultimately transforming the therapeutic landscape for cancer patients.

Coherus is relentlessly focused on advancing a diversified portfolio of next-generation immuno-oncology therapies. Our pipeline includes several clinical-stage drug candidates that strategically target the tumor microenvironment, a critical area in cancer progression and treatment resistance. We are committed to rigorous scientific validation and are conducting multiple ongoing clinical trials across a spectrum of cancer indications to assess the safety and efficacy of our investigational therapeutics. This includes LOQTORZI™ (toripalimab-tpzi), a novel PD-1 inhibitor, and other promising candidates like casdozokitug, an IL-27 antagonistic antibody. By pushing the boundaries of scientific discovery and maintaining an unwavering dedication to patients, Coherus BioSciences is striving to make a profound impact on the lives of those affected by cancer, offering new hope through cutting-edge treatments and a vision for a future where more cancers are manageable and curable.